JP7720914B2 - ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法 - Google Patents
ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法Info
- Publication number
- JP7720914B2 JP7720914B2 JP2023538962A JP2023538962A JP7720914B2 JP 7720914 B2 JP7720914 B2 JP 7720914B2 JP 2023538962 A JP2023538962 A JP 2023538962A JP 2023538962 A JP2023538962 A JP 2023538962A JP 7720914 B2 JP7720914 B2 JP 7720914B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- amount
- less
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/139524 | 2020-12-25 | ||
| PCT/CN2020/139524 WO2022134033A1 (en) | 2020-12-25 | 2020-12-25 | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PCT/US2021/064947 WO2022140600A1 (en) | 2020-12-25 | 2021-12-22 | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501956A JP2024501956A (ja) | 2024-01-17 |
| JP2024501956A5 JP2024501956A5 (cg-RX-API-DMAC7.html) | 2024-07-22 |
| JP7720914B2 true JP7720914B2 (ja) | 2025-08-08 |
Family
ID=82157262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538962A Active JP7720914B2 (ja) | 2020-12-25 | 2021-12-22 | ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12152028B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267577A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7720914B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230124985A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116867780A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021410756B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202354A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304005A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007404A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2022134033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2024077169A1 (en) | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| WO2026132432A1 (en) | 2024-12-20 | 2026-06-25 | Curia Spain, S.A.U. | Relacorilant crystalline forms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013177559A2 (en) | 2012-05-25 | 2013-11-28 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| DE69430373T2 (de) | 1993-08-06 | 2002-12-12 | Smithkline Beecham S.P.A., Baranzate Di Bollate | Hydroisochinolinderivate |
| US5688808A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| JP4498602B2 (ja) | 1998-03-10 | 2010-07-07 | リサーチ・トライアングル・インスティチュート | 新規なオピエート化合物、その調製法及び使用法 |
| US6166013A (en) | 1998-07-30 | 2000-12-26 | Abbott Laboratories | Glucocortiocoid-selective agents |
| AU2620600A (en) | 1999-01-21 | 2000-08-07 | Steroidogenesis Inhibitors International | Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| GB0010683D0 (en) | 2000-05-03 | 2000-06-28 | Univ Bristol | Cancer therapy |
| US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| CN1547473A (zh) | 2001-07-23 | 2004-11-17 | �Ƹ��� | 预防由抗精神病药物引起的体重增加的方法 |
| ATE411013T1 (de) | 2001-08-31 | 2008-10-15 | Corcept Therapeutics Inc | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1534299A4 (en) | 2002-07-02 | 2007-04-11 | Corcept Therapeutics Inc | METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| AU2004208842B2 (en) | 2003-02-04 | 2009-05-28 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of postpartum psychosis |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
| CA2552419C (en) | 2004-01-09 | 2013-04-23 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| EP1723174A1 (en) | 2004-02-26 | 2006-11-22 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | A novel modulator of glucocorticoid receptor activities |
| JP4931794B2 (ja) | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス, インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| US7576076B2 (en) | 2004-07-02 | 2009-08-18 | Corcept Therapeutics, Inc. | Modified pyrimidine glucocorticoid receptor modulators |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| US20090156672A1 (en) | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20110166115A1 (en) | 2008-07-01 | 2011-07-07 | Corcept Therapeutics, Inc. | Use of mifepristone for the treatment of amyotrophic lateral sclerosis |
| US20100135956A1 (en) | 2008-11-21 | 2010-06-03 | Auspex Pharmaceuticals, Inc. | Steroid modulators of progesterone receptor and/or glucocorticoid receptor |
| AU2010247766B2 (en) | 2009-05-12 | 2015-05-21 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| BR112013004322A2 (pt) | 2010-08-27 | 2016-06-21 | Corcept Therapeutics Inc | moduladores de azadecalin fundidos com piridil-aminas |
| US8658128B2 (en) | 2011-02-03 | 2014-02-25 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| CN103596431B (zh) | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| MX370976B (es) | 2011-11-11 | 2020-01-10 | Gilead Apollo Llc | Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos. |
| ES2991315T3 (es) | 2012-02-24 | 2024-12-03 | Univ Chicago | Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata |
| WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| ES2943542T3 (es) | 2013-11-25 | 2023-06-14 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| US10532150B2 (en) | 2014-07-21 | 2020-01-14 | Medtronic Minimed, Inc. | Smart connection interface |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| EP3233916A4 (en) | 2014-12-19 | 2018-06-06 | Alder Biopharmaceuticals, Inc. | Humanized anti-acth antibodies and use thereof |
| JP6821582B2 (ja) | 2015-03-02 | 2021-01-27 | コーセプト セラピューティクス, インコーポレイテッド | Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用 |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| US9598459B2 (en) | 2015-08-03 | 2017-03-21 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| MX383318B (es) | 2015-08-13 | 2025-03-13 | Corcept Therapeutics Inc | Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina. |
| AU2017228329B2 (en) * | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| PH12017000049B1 (en) | 2017-02-20 | 2018-08-29 | Peter S Heilveil | Aerial cable spacer |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| NZ778399A (en) * | 2019-02-22 | 2024-11-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| JP2023515781A (ja) | 2020-02-10 | 2023-04-14 | コーセプト セラピューティクス, インコーポレイテッド | 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| AU2023301396A1 (en) | 2022-06-28 | 2024-12-12 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2024077169A1 (en) | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
-
2020
- 2020-12-25 WO PCT/CN2020/139524 patent/WO2022134033A1/en not_active Ceased
-
2021
- 2021-12-22 JP JP2023538962A patent/JP7720914B2/ja active Active
- 2021-12-22 EP EP21912180.3A patent/EP4267577A4/en active Pending
- 2021-12-22 WO PCT/US2021/064947 patent/WO2022140600A1/en not_active Ceased
- 2021-12-22 US US17/560,048 patent/US12152028B2/en active Active
- 2021-12-22 MX MX2023007404A patent/MX2023007404A/es unknown
- 2021-12-22 IL IL304005A patent/IL304005A/en unknown
- 2021-12-22 KR KR1020237024682A patent/KR20230124985A/ko active Pending
- 2021-12-22 AU AU2021410756A patent/AU2021410756B2/en active Active
- 2021-12-22 CN CN202180091897.1A patent/CN116867780A/zh active Pending
- 2021-12-22 CA CA3202354A patent/CA3202354A1/en active Pending
-
2024
- 2024-10-18 US US18/920,639 patent/US20250145620A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203341A patent/AU2025203341B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013177559A2 (en) | 2012-05-25 | 2013-11-28 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Non-Patent Citations (1)
| Title |
|---|
| HUNT, Hazel J. et al.,Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist,Journal of Medicinal Chemistry,2017年,60 (8),3405-3421 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024501956A (ja) | 2024-01-17 |
| AU2025203341A1 (en) | 2025-05-29 |
| KR20230124985A (ko) | 2023-08-28 |
| AU2025203341B2 (en) | 2026-03-05 |
| AU2021410756A1 (en) | 2023-07-06 |
| MX2023007404A (es) | 2023-08-21 |
| WO2022140600A1 (en) | 2022-06-30 |
| IL304005A (en) | 2023-08-01 |
| CA3202354A1 (en) | 2022-06-30 |
| US20220227753A1 (en) | 2022-07-21 |
| US12152028B2 (en) | 2024-11-26 |
| CN116867780A (zh) | 2023-10-10 |
| AU2021410756B2 (en) | 2025-02-13 |
| WO2022134033A1 (en) | 2022-06-30 |
| EP4267577A4 (en) | 2024-11-27 |
| US20250145620A1 (en) | 2025-05-08 |
| AU2021410756A9 (en) | 2024-09-12 |
| EP4267577A1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102911885B1 (ko) | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체 | |
| US20250145620A1 (en) | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| JP6172871B2 (ja) | ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子 | |
| EP2499151A2 (en) | Mammalian metabolites of steroids | |
| JP2025522619A (ja) | ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240711 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250502 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250708 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250729 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7720914 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |